MedTrace Logo

Gut Peptides and Bone Remodeling in Individuals With Spinal Cord Injury

NCT05181150 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-05-10

No results posted yet for this study

Summary

Both GLP-2 and GIP reduce bone resorption (measured as CTX) in healthy persons. In this study, we will investigate whether GLP-2 and GIP is reducing CTX in individuals with spinal cord injury.

Conditions

  • Spinal Cord Injuries

Interventions

OTHER

Meal test

Ingestion of an oral liquid meal (nutridrink), 200 mL.

OTHER

GIP

Subcutaneous GIP injection.

OTHER

GLP-2

Subcutaneous GLP-2 injection.

OTHER

GIP + GLP-2

Subcutaneous GIP + GLP-2 injection.

OTHER

Placebo

Subcutaneous saline injection.

Sponsors & Collaborators

  • Hvidovre University Hospital

    collaborator OTHER

  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Mette M Rosenkilde, Prof., MD · University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-16
Primary Completion
2024-11-30
Completion
2024-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05181150 on ClinicalTrials.gov